Logo image of PRVB

PROVENTION BIO INC (PRVB) Stock Fundamental Analysis

NASDAQ:PRVB - Nasdaq - US74374N1028 - Common Stock - Currency: USD

24.98  +0.75 (+3.1%)

After market: 25 +0.02 (+0.08%)

Fundamental Rating

2

PRVB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. PRVB may be in some trouble as it scores bad on both profitability and health. PRVB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRVB had negative earnings in the past year.
PRVB had a negative operating cash flow in the past year.
In the past 5 years PRVB always reported negative net income.
In the past 5 years PRVB always reported negative operating cash flow.
PRVB Yearly Net Income VS EBIT VS OCF VS FCFPRVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

PRVB has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRVB Yearly ROA, ROE, ROICPRVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 96.03%, PRVB belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
PRVB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRVB Yearly Profit, Operating, Gross MarginsPRVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

PRVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRVB has more shares outstanding than it did 1 year ago.
PRVB has a worse debt/assets ratio than last year.
PRVB Yearly Shares OutstandingPRVB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
PRVB Yearly Total Debt VS Total AssetsPRVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 8.65 indicates that PRVB is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.65, PRVB belongs to the top of the industry, outperforming 87.61% of the companies in the same industry.
A Debt/Equity ratio of 0.19 indicates that PRVB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.19, PRVB perfoms like the industry average, outperforming 43.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 8.65
ROIC/WACCN/A
WACC8.84%
PRVB Yearly LT Debt VS Equity VS FCFPRVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

PRVB has a Current Ratio of 1.93. This is a normal value and indicates that PRVB is financially healthy and should not expect problems in meeting its short term obligations.
PRVB's Current ratio of 1.93 is on the low side compared to the rest of the industry. PRVB is outperformed by 65.60% of its industry peers.
PRVB has a Quick Ratio of 1.92. This is a normal value and indicates that PRVB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.92, PRVB is doing worse than 61.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.92
PRVB Yearly Current Assets VS Current LiabilitesPRVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

PRVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.09%, which is quite good.
Looking at the last year, PRVB shows a very strong growth in Revenue. The Revenue has grown by 824.37%.
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%

3.2 Future

PRVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.69% yearly.
PRVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.71% yearly.
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%

3.3 Evolution

PRVB Yearly Revenue VS EstimatesPRVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
PRVB Yearly EPS VS EstimatesPRVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRVB Price Earnings VS Forward Price EarningsPRVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRVB Per share dataPRVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PRVB's earnings are expected to grow with 36.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y36.47%

More info and screens

0

5. Dividend

5.1 Amount

PRVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROVENTION BIO INC

NASDAQ:PRVB (4/26/2023, 8:02:36 PM)

After market: 25 +0.02 (+0.08%)

24.98

+0.75 (+3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-04 2023-05-04/bmo
Earnings (Next)08-02 2023-08-02/bmo
Inst Owners0.27%
Inst Owner Change0%
Ins Owners7.34%
Ins Owner Change0%
Market Cap2.37B
Analysts78.33
Price Target24.48 (-2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.45%
Min EPS beat(2)3.79%
Max EPS beat(2)21.1%
EPS beat(4)4
Avg EPS beat(4)15.24%
Min EPS beat(4)3.79%
Max EPS beat(4)26.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)11.53%
Min Revenue beat(2)-4.73%
Max Revenue beat(2)27.78%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-18.77%
Max Revenue beat(4)27.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.74%
EPS NQ rev (1m)-79.31%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-1.57%
EPS NY rev (3m)-3.75%
Revenue NQ rev (1m)-39.66%
Revenue NQ rev (3m)-12.5%
Revenue NY rev (1m)-22.86%
Revenue NY rev (3m)-17.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 183.61
P/FCF N/A
P/OCF N/A
P/B 19.43
P/tB 38.01
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.14
BVpS1.29
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.92
Altman-Z 8.65
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)1337.69%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%
EBIT growth 1Y-10.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.94%
OCF growth 3YN/A
OCF growth 5YN/A